1. Home
  2. STOK

STOK

Stoke Therapeutics Inc.

Logo Stoke Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.

Founded: 2014 Country:
United States
United States
Employees: N/A City: BEDFORD
Market Cap: 662.2M IPO Year: 2019
Target Price: $20.43 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.38 EPS Growth: N/A
52 Week Low/High: $3.35 - $16.40 Next Earning Date: 05-02-2024
Revenue: $8,780,000 Revenue Growth: -29.22%
Revenue Growth (this year): 43.28% Revenue Growth (next year): 27.55%

Share on Social Networks: